Please assess the completion status of the following clinical trial:

Trial Title: Effect of a Basal/Pre-Meal Insulin Strategy (Detemir/Aspart) on Insulin Secretion and Action in Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~To participate patients must:~1. Be able to communicate meaningfully with the Investigator and be legally competent to provide written informed consent.~2. Female patients must be non-lactating and must either be at least two years post-menopausal, or be using adequate contraceptive precautions (i.e. oral contraceptives, approved hormonal implant, intrauterine device, diaphragm with spermicide, condom with spermicide), or be surgically sterilized (i.e. bilateral tubal ligation, bilateral oophorectomy). Female patients who have undergone a hysterectomy are eligible for participation in the study. Female patients (except for those patients who have undergone a hysterectomy or a bilateral oophorectomy) are eligible only if they have a negative pregnancy test throughout the study period.~3. Age range of 18 to 70 years (inclusive).~4. Patients must have been on a stable dose of allowed chronic medications for two months prior to entering the double-blind treatment period.~5. All participants must have the following laboratory values:~   * Hemoglobin ≥ 12 g/dl in males or ≥ 11 g/dl in females~  * Serum creatinine ≤ 1.5 mg/dl~  * AST (SGOT) ≤ 2.5 times upper limit of normal~  * ALT (SGPT) ≤ 2.5 times upper limit of normal~  * Alkaline phosphatase ≤ 2.5 times upper limit of normal~Exclusion Criteria:~Patients will be excluded if any of the following criteria are present:~1. Individuals with type 1 diabetes or type 2 diabetes and a FPG ≥ 300 mg/dl.~2. Subjects on sulfonylureas, metformin and/or TZDs unless the dose has been stable for at least 2 months prior to study entry.~3. Patients on any of the following medications: thiazide or furosemide diuretics, beta-blockers, or other chronic medications with known adverse effects on glucose tolerance levels unless the patient has been on stable doses of such agents for the past two months before entry into the study. Patients may be taking stable doses of estrogens or other hormonal replacement therapy if the patient has been on these agents for the prior two months. Patients taking systemic glucocorticoids will be excluded.~4. Past (within 1 year) or current history of alcohol abuse.~5. Patients will be excluded if there is a history of clinically significant heart disease (New York Heart Classification greater than grade II), peripheral vascular disease (history of claudication), or pulmonary disease (dyspnea on exertion of one flight or less; abnormal breath sounds on auscultation) or chronic renal failure (serum creatinine greater than 1.5 mg/dl).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Insulin detemir only (Type: ACTIVE_COMPARATOR): Patients with uncontrolled T2DM are treated with insulin detemir for 6 months. Insulin detemir is given at bedtime aiming at a fasting plasma glucose between 80-100 mg/dl. This group will receive Long-acting bedtime insulin detemir (Levemir).
- Insulin detemir plus aspart (Type: EXPERIMENTAL): After baseline evaluations, insulin detemir will be given at bedtime and titrated to achieve a fasting plasma glucose between 80-100 mg/dl. After 3 months patients will be admitted to assess the metabolic effects of intervention. After this, insulin aspart (insulin detemir plus aspart) will be added before breakfast, lunch and dinner titrated to normalize the postprandial plasma glucose. After another 3 months patients are readmitted and all study procedures repeated. This group will receive Insulin detemir and pre-meal insulin aspart.

Based on this trial design, predict the completion outcome and termination type (if applicable).